E-Mail Newsletter (MLL News)

Our newsletter is an offer of MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich (“MLL,” “we”) and contains information about our products and services, research results, events and other news relevant to the company and to the discipline, especially regarding diagnostics and subsequent therapy for leukemia and lymphoma. For you to subscribe, we need the e-mail address that you want us to send the newsletter to. We may use optional information to personalize how the addressee is addressed.
To continuously improve the quality of our newsletter and its contents, we conduct a pseudonymized analysis of the opening rate of the newsletter and information on calling up specific articles. You can find detailed information on how personal data is processed in connection with our newsletter in our Data protection information section.

By clicking on the “Subscribe to the newsletter” button, I consent to allow MLL to use the e-mail address and optional information provided by me for sending the newsletter and for addressing me personally.


Newsletter registration

You have the right to withdraw your consent at any time. Withdrawing your consent does not affect the lawfulness of the processing that took place based on your consent up until the time of withdrawal. One way you can withdraw your consent is by using the withdrawal function contained in every newsletter. Alternatively, you can declare that you are withdrawing your consent by sending an e-mail to or by mailing a letter to MLL Münchner Leukämielabor GmbH, Max-Lebsche-Platz 31, 81377 Munich.

MLL Magazine

Stay up to date

Here you will find all MLL News as well as scientific contributions to leukemia diagnostics and research.

to the MLL Magazine

Current Articles

  • Dr. rer. nat. Frank Dicker
    from 14.06.2021
    4-stage (4-tier) system for evaluating sequence variants

    Sequence alterations have classically been divided into two categories: "mutation" and "polymorphism". However, the rapid increase in sequencing data from healthy and various diseased tissues has made it obvious that there is a broad spectrum between clearly disease-associated pathogenic alterations and non-pathogenic polymorphisms. As of now, we are working in molecular genetics with the world's most widely used 4-tier classification system, which we have adapted to central questions in hematological diagnostics. We would like to introduce this to you in this article.

    Post review
    Read article
  • Prof. Dr. med. Dr. phil. Torsten Haferlach
    from 11.06.2021
    The logic of next generation sequencing wherever myeloid neoplasia is suspected

    Recently, S. Vantyghem et al (Haematologica 3/1/2021, pages 701–707) published a “real-life study.” The analyses were focused on 177 patients with suspected or already confirmed myeloid neoplasias such as MDS or MPN without a final diagnosis using cytomorphology and immunophenotyping. In a first cohort, an NGS panel with 34 genes was used either to exclude or confirm a definitive diagnosis. In a second cohort, the extent to which prognostic and especially therapeutic consequences would have to be drawn if somatic mutations were detectable was investigated. I would like to introduce this study to you in this article.

    Post review
    Read article



Sarah Kurz

MLL Münchner Leukämielabor GmbH
Max-Lebsche-Platz 31
81377 München

T: +49 (0)89 99017-547

Getting here